These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28222634)

  • 41. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan.
    Qarawani D; Cohen A; Nahir M; Hasin Y
    Int J Cardiol; 2013 Sep; 168(1):237-42. PubMed ID: 23063476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study.
    Dernellis J; Panaretou M
    Chest; 2005 Oct; 128(4):2633-9. PubMed ID: 16236936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preoperative levosimendan in heart failure patients undergoing noncardiac surgery.
    Katsaragakis S; Kapralou A; Markogiannakis H; Kofinas G; Theodoraki EM; Larentzakis A; Menenakos E; Theodorou D
    Neth J Med; 2008 Apr; 66(4):154-9. PubMed ID: 18424862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
    J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levosimendan in cardiac failure after subarachnoid hemorrhage.
    Busani S; Rinaldi L; Severino C; Cobelli M; Pasetto A; Girardis M
    J Trauma; 2010 May; 68(5):E108-10. PubMed ID: 20453750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
    Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
    Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The effects of levosimendan on the cardiac function and prognosis in elderly patients with septic shock and myocardial contractility impairment].
    Xu CX; Li L; Gong SJ; Yu YH; Yan J
    Zhonghua Nei Ke Za Zhi; 2018 Jun; 57(6):423-428. PubMed ID: 29925127
    [No Abstract]   [Full Text] [Related]  

  • 54. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
    Erb J; Beutlhauser T; Feldheiser A; Schuster B; Treskatsch S; Grubitzsch H; Spies C
    J Int Med Res; 2014 Jun; 42(3):750-64. PubMed ID: 24781725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
    Feola M; Lombardo E; Taglieri C; Vallauri P; Piccolo S; Valle R
    Med Sci Monit; 2011 Feb; 17(3):PI7-13. PubMed ID: 21358614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
    Packer M; Colucci W; Fisher L; Massie BM; Teerlink JR; Young J; Padley RJ; Thakkar R; Delgado-Herrera L; Salon J; Garratt C; Huang B; Sarapohja T;
    JACC Heart Fail; 2013 Apr; 1(2):103-11. PubMed ID: 24621834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure.
    Tziakas DN; Chalikias GK; Hatzinikolaou HI; Stakos DA; Papanas N; Tentes IK; Kortsaris AX; Maltezos E; Hatseras DI; Kaski JC
    Cardiovasc Drugs Ther; 2005 Dec; 19(6):399-402. PubMed ID: 16435069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.